These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 5157730)

  • 1. Pharmacokinetics of cyclophosphamide in man.
    Cohen JL; Jao JY; Jusko WJ
    Br J Pharmacol; 1971 Nov; 43(3):677-80. PubMed ID: 5157730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenobarbital effects on cyclophosphamide pharmacokinetics in man.
    Jao JY; Jusko WJ; Cohen JL
    Cancer Res; 1972 Dec; 32(12):2761-4. PubMed ID: 4678592
    [No Abstract]   [Full Text] [Related]  

  • 3. Simultaneous tubular excretion and reabsorption of pindolol in man.
    Balant L; Muir K; Dayer P; Gorgia A; Eberlin JL; Estreicher J; Fabre J
    Eur J Clin Pharmacol; 1981; 21(1):65-72. PubMed ID: 7333348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The biotransformation of cyclophosphamide in man: analysis of the variation in normal subjects.
    Mouridsen HT; Faber O; Skovsted L
    Acta Pharmacol Toxicol (Copenh); 1974 Aug; 35(2):98-106. PubMed ID: 4479366
    [No Abstract]   [Full Text] [Related]  

  • 5. Studies on the human pharmacokinetics of isophosphamide (NSC-109724).
    Allen LM; Creaven PJ; Nelson RL
    Cancer Treat Rep; 1976 Apr; 60(4):451-8. PubMed ID: 1277221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PLasma half-life and urinary excretion of cyclophosphamide in children.
    Sladek NE; Priest J; Doeden D; Mirocha CJ; Pathre S; Krivit W
    Cancer Treat Rep; 1980; 64(10-11):1061-6. PubMed ID: 7459891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of phenobarbital and SKF 525A on the toxicity, elimination and metabolism of cyclophosphamide in newborn mice.
    Bus JS; Short RD; Gibson JE
    J Pharmacol Exp Ther; 1973 Mar; 184(3):749-56. PubMed ID: 4687235
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical pharmacology of cyclophosphamide.
    Bagley CM; Bostick FW; DeVita VT
    Cancer Res; 1973 Feb; 33(2):226-33. PubMed ID: 4688880
    [No Abstract]   [Full Text] [Related]  

  • 9. Clearance and recovery calculations in hemodialysis: application to plasma, red blood cells, and dialysate measurements for cyclophosphamide.
    Wang LH; Lee CS; Majeske BL; Marbury TC
    Clin Pharmacol Ther; 1981 Mar; 29(3):365-72. PubMed ID: 7471607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comparative pharmacology of cyclophosphamide and ifosfamide.
    Colvin M
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):2-7. PubMed ID: 6761865
    [No Abstract]   [Full Text] [Related]  

  • 11. Studies on the pharmacokinetics of cyclophosphamide in sheep.
    Schaumlöffel E; Habermehl A; Brock N; Schneider B
    Arzneimittelforschung; 1973 Apr; 23(4):491-500. PubMed ID: 4740226
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effect of damaged liver parenchyma, renal insufficiency and hemodialysis on the pharmacokinetics of cyclophosphamide and its activated metabolites].
    Wagner T; Heydrich D; Bartels H; Hohorst HJ
    Arzneimittelforschung; 1980; 30(9):1588-92. PubMed ID: 7193030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
    Chen TL; Kennedy MJ; Anderson LW; Kiraly SB; Black KC; Colvin OM; Grochow LB
    Drug Metab Dispos; 1997 May; 25(5):544-51. PubMed ID: 9152592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The biotransformation of cyclophosphamide in man: influence of prednisone.
    Faber OK; Mouridsen HT; Skovsted L
    Acta Pharmacol Toxicol (Copenh); 1974 Sep; 35(3):195-200. PubMed ID: 4479295
    [No Abstract]   [Full Text] [Related]  

  • 15. Plasma levels and urinary excretion of ( 14 C)cyclophosphamide and its radioactive metabolites in rats pretreated with prednisolone.
    Hanasono GK; Fischer LJ
    Biochem Pharmacol; 1972 Jan; 21(2):272-6. PubMed ID: 4645560
    [No Abstract]   [Full Text] [Related]  

  • 16. Validation of urinary excretion of cyclophosphamide as a biomarker of exposure by studying its renal clearance at high and low plasma concentrations in cancer patients.
    Hedmer M; Höglund P; Cavallin-Ståhl E; Albin M; Jönsson BA
    Int Arch Occup Environ Health; 2008 Jan; 81(3):285-93. PubMed ID: 17579883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration.
    Juma FD; Rogers HJ; Trounce JR
    Br J Clin Pharmacol; 1979 Sep; 8(3):209-17. PubMed ID: 497087
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of chloramphenicol and sulphaphenazole on the biotransformation of cyclophosphamide in man.
    Faber OK; Mouridsen HT; Skovsted L
    Br J Clin Pharmacol; 1975 Jun; 2(3):281-5. PubMed ID: 791322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of cyclophosphamide in renal failure.
    Mouridsen HT; Jacobsen E
    Acta Pharmacol Toxicol (Copenh); 1975; 36(Suppl 5):409-14. PubMed ID: 1173530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics of cyclophosphamide in man after treatment with allopurinol.
    Witten J; Frederiksen PL; Mouridsen HT
    Acta Pharmacol Toxicol (Copenh); 1980 May; 46(5):392-4. PubMed ID: 7376891
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.